A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results

Andrew Zolopa, Paul E. Sax, Edwin Dejesus, Anthony Mills, Calvin Cohen, David Wohl, Joel E. Gallant, Hui C. Liu, Andrew Plummer, Kirsten L. White, Andrew K. Cheng, Martin S. Rhee, Javier Szwarcberg

Research output: Contribution to journalArticle

Abstract

We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88% vs 84%, difference +3.6%, 95% confidence interval: -1.6% to 8.8%). Virologic success (HIV-1 RNA

Original languageEnglish (US)
Pages (from-to)96-100
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume63
Issue number1
DOIs
StatePublished - May 1 2013

Fingerprint

Tenofovir
efavirenz
HIV Infections
HIV-1
RNA
Confidence Intervals
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Emtricitabine

Keywords

  • cobicistat
  • efficacy
  • HIV
  • phase 3 randomized trial
  • safety
  • stribild

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection : Analysis of week 96 results. / Zolopa, Andrew; Sax, Paul E.; Dejesus, Edwin; Mills, Anthony; Cohen, Calvin; Wohl, David; Gallant, Joel E.; Liu, Hui C.; Plummer, Andrew; White, Kirsten L.; Cheng, Andrew K.; Rhee, Martin S.; Szwarcberg, Javier.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 63, No. 1, 01.05.2013, p. 96-100.

Research output: Contribution to journalArticle

Zolopa, Andrew ; Sax, Paul E. ; Dejesus, Edwin ; Mills, Anthony ; Cohen, Calvin ; Wohl, David ; Gallant, Joel E. ; Liu, Hui C. ; Plummer, Andrew ; White, Kirsten L. ; Cheng, Andrew K. ; Rhee, Martin S. ; Szwarcberg, Javier. / A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection : Analysis of week 96 results. In: Journal of Acquired Immune Deficiency Syndromes. 2013 ; Vol. 63, No. 1. pp. 96-100.
@article{3597c8cc4754446fb18339eaba58d458,
title = "A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results",
abstract = "We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88{\%} vs 84{\%}, difference +3.6{\%}, 95{\%} confidence interval: -1.6{\%} to 8.8{\%}). Virologic success (HIV-1 RNA",
keywords = "cobicistat, efficacy, HIV, phase 3 randomized trial, safety, stribild",
author = "Andrew Zolopa and Sax, {Paul E.} and Edwin Dejesus and Anthony Mills and Calvin Cohen and David Wohl and Gallant, {Joel E.} and Liu, {Hui C.} and Andrew Plummer and White, {Kirsten L.} and Cheng, {Andrew K.} and Rhee, {Martin S.} and Javier Szwarcberg",
year = "2013",
month = "5",
day = "1",
doi = "10.1097/QAI.0b013e318289545c",
language = "English (US)",
volume = "63",
pages = "96--100",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection

T2 - Analysis of week 96 results

AU - Zolopa, Andrew

AU - Sax, Paul E.

AU - Dejesus, Edwin

AU - Mills, Anthony

AU - Cohen, Calvin

AU - Wohl, David

AU - Gallant, Joel E.

AU - Liu, Hui C.

AU - Plummer, Andrew

AU - White, Kirsten L.

AU - Cheng, Andrew K.

AU - Rhee, Martin S.

AU - Szwarcberg, Javier

PY - 2013/5/1

Y1 - 2013/5/1

N2 - We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88% vs 84%, difference +3.6%, 95% confidence interval: -1.6% to 8.8%). Virologic success (HIV-1 RNA

AB - We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88% vs 84%, difference +3.6%, 95% confidence interval: -1.6% to 8.8%). Virologic success (HIV-1 RNA

KW - cobicistat

KW - efficacy

KW - HIV

KW - phase 3 randomized trial

KW - safety

KW - stribild

UR - http://www.scopus.com/inward/record.url?scp=84876283495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876283495&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e318289545c

DO - 10.1097/QAI.0b013e318289545c

M3 - Article

C2 - 23392460

AN - SCOPUS:84876283495

VL - 63

SP - 96

EP - 100

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -